Concepedia

Author

Niels Viggo Jensen

Odense University HospitalORCID

Also Known As

Anne Birgitte Als, Jensen, N.V., Jensen, Niels V., N Jensen, N. Jensen, N.V. Jensen, Niels V. Jensen, Niels Viggo Jensen, Scott North, V Jensen, N

51

Publications

1.3K

Citations

14

H-Index

16

Concepts

All Affiliations

Odense University HospitalAarhus University HospitalRigshospitaletHerlev HospitalUniversity of Copenhagen
NV

About

Niels Viggo Jensen is an author at Odense University Hospital specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

357

2

Pathology

1

1

14

3

Pharmacology

1

1

10

4

Surgical Oncology

1

1

25

5

Cancer Epidemiology

1

1

50

Niels Viggo Jensen

×

16

Publications

693

Citations

13

H-Index

YearCitations

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N.,

The Lancet

2017

175

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason,

Journal of Clinical Oncology

2021

122

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N.,

The Lancet Oncology

2019

83

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

Anne Vest Soerensen, Frede Donskov, Gregers G. Hermann,

European Journal of Cancer

2013

76

The influence of chemotherapy on survival after recurrence in breast cancer—a population-based study of patients treated in the 1950s, 1960s and 1970s

Søren Cold, Niels Viggo Jensen, H Brincker,

European Journal of Cancer

1993

50

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Frede Donskov, Robert J. Motzer, Éric Voog,

European Journal of Cancer

2019

26

1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial

Jørgen Bjerggaard Jensen, Karin Birkenkamp‐Demtröder, Iver Nordentoft,

Annals of Oncology

2024

25

Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)

Karin Holmsten, Niels Viggo Jensen, Lene Sonne Mouritsen,

European Journal of Cancer

2019

22

A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

Frede Donskov, Niels Viggo Jensen, Torben Smidt-Hansen,

Acta Oncologica

2018

20

Trends in kidney cancer among the elderly in Denmark, 1980–2012

Nessn Azawi, Simon Moeller Joergensen, Niels Viggo Jensen,

Acta Oncologica

2016

19

Page 1